Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...

MDS and AML are cognate, clonal hematological neoplasms and have variable outcomes despite the recent, successful implementation of targeted therapies. However, the hope for improved outcomes might be ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still ...

The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.